Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial
The Oncologist · 2024
DOI: 10.1093/oncolo/oyae096 ↗Kurz gefasst
Klinische Studie in der Zeitschrift The Oncologist, 2024. Verfasst von Julia L Glade Bender und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, United States. Hauptthemen laut MEDLINE: DNA Repair, Neoplasms, Phthalazines, Piperazines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
The National Cancer Institute-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice (MATCH) precision oncology platform trial enrolled children aged 1-21 years with treatment-refractory solid tumors and predefined actionable genetic alterations. Patients with tumors harboring alterations in DNA damage repair (DDR) genes were assigned to receive olaparib.
Methods
Tumor and blood samples were submitted for centralized molecular testing. Tumor and germline sequencing were conducted in parallel. Olaparib was given twice daily for 28-day cycles starting at a dose 30% lower than the adult recommended phase 2 dose (RP2D). The primary endpoint was the objective response.
Results
Eighteen patients matched (1.5% of those screened) based on the presence of a deleterious gene alteration in BRCA1/2, RAD51C/D, or ATM detected by tumor sequencing without germline subtraction or analysis of loss of heterozygosity (LOH). Eleven (61%) harbored a germline mutation, with only one exhibiting LOH. Six patients enrolled and received the olaparib starting dose of 135 mg/m2/dose. Two participants were fully evaluable; 4 were inevaluable because <85% of the prescribed dose was administered during cycle 1. There were no dose-limiting toxicities or responses. Minimal hematologic toxicity was observed.
Conclusion
Most DDR gene alterations detected in Pediatric MATCH were germline, monoallelic, and unlikely to confer homologous recombination deficiency predicting sensitivity to olaparib monotherapy. The study closed due to poor accrual. ClinicalTrials.gov Identifier NCT03233204. IRB approved: initial July 24, 2017.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
- Department of Hematology-Oncology, Memorial Regional Hospital/Joe Dimaggio Children's Hospital, Hollywood, FL, United States.
- Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
- Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
- Center for Biomedical Informatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, United States.
ORCID-Profile: Julia L Glade Bender, Sinchita Roy-Chowdhuri, Joel M Reid, Douglas S Hawkins, Margaret M Mooney
Förderung
- NCI NIH HHS
Zitieren
APA
Glade Bender, J. L., Pinkney, K., Williams, P. M., Roy-Chowdhuri, S., Patton, D. R., Coffey, B. D., Reid, J. M., Piao, J., Saguilig, L., Alonzo, T. A., Berg, S. L., Ramirez, N. C., Fox, E., Weigel, B. J., Hawkins, D. S., Mooney, M. M., Takebe, N., Tricoli, J. V., Janeway, K. A., …, & Parsons, D. W. (2024). Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial. The Oncologist. https://doi.org/10.1093/oncolo/oyae096
Vancouver
Glade Bender JL, Pinkney K, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey BD, et al. Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial. The Oncologist. 2024. doi:10.1093/oncolo/oyae096
BibTeX
@article{GladeBender2024,
author = {Glade Bender, Julia L and Pinkney, Kerice and Williams, Paul M and Roy-Chowdhuri, Sinchita and Patton, David R and Coffey, Brent D and Reid, Joel M and Piao, Jin and Saguilig, Lauren and Alonzo, Todd A and Berg, Stacey L and Ramirez, Nilsa C and Fox, Elizabeth and Weigel, Brenda J and Hawkins, Douglas S and Mooney, Margaret M and Takebe, Naoko and Tricoli, James V and Janeway, Katherine A and Seibel, Nita L and Parsons, Donald W},
title = {Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial},
journal = {The Oncologist},
year = {2024},
doi = {10.1093/oncolo/oyae096}
}
EUVIMED